GT Biopharma Inc (GTBP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.22 (-3.60%), Market cap $0.01B, 52-week low–high $0.27 ~ $3.80.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed
Financial statements, price targets, institutional (13F) holdings and related news for GT Biopharma Inc are updated in real time on BlackAll Trade.
GT Biopharma Inc trades at $7.22 (-3.60%). Real-time quotes and charts are available on BlackAll Trade.
GT Biopharma Inc has a market cap of about $0.01B.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-